Immunome, Inc. (NASDAQ:IMNM – Get Free Report)’s stock price hit a new 52-week low on Friday. The company traded as low as $16.38 and last traded at $16.3930, with a volume of 561 shares changing hands. The stock had previously closed at $16.61.
Analysts Set New Price Targets
IMNM has been the topic of a number of recent research reports. Stifel Nicolaus cut their target price on shares of Immunome from $24.00 to $23.00 and set a “hold” rating on the stock in a report on Tuesday, November 10th. Alliance Global Partners assumed coverage on Immunome in a report on Monday, September 21st. They issued a “buy” rating and a $32.00 price target on the stock. Wall Street Zen lowered Immunome from a “sell” rating to a “strong sell” rating in a research report on Sunday, October 4th. Wedbush restated an “outperform” rating and set a $35.00 price objective on shares of Immunome in a research report on Tuesday, October 27th. Finally, William Blair started coverage on Immunome in a research report on Friday, October 16th. They issued an “outperform” rating on the stock. Fourteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Immunome has a consensus rating of “Moderate Buy” and an average price target of $33.85.
View Our Latest Stock Analysis on IMNM
Immunome Price Performance
Immunome (NASDAQ:IMNM – Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.14). As a group, analysts forecast that Immunome, Inc. will post -2.64 earnings per share for the current year.
Insider Transactions at Immunome
In other Immunome news, insider Jack Higgins sold 13,200 shares of the business’s stock in a transaction on Friday, September 11th. The stock was sold at an average price of $25.32, for a total transaction of $334,224.00. Following the completion of the transaction, the insider owned 65,050 shares in the company, valued at approximately $1,647,066. The trade was a 16.87% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 7.21% of the company’s stock.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the business. Allworth Financial LP acquired a new stake in Immunome in the second quarter worth about $25,000. Integrated Wealth Concepts LLC acquired a new position in Immunome during the 2nd quarter valued at about $27,000. KBC Group NV acquired a new position in Immunome during the 1st quarter valued at about $60,000. GK Wealth Management LLC bought a new stake in shares of Immunome during the 3rd quarter worth about $71,000. Finally, Sterling Capital Management LLC raised its position in shares of Immunome by 840.0% during the 3rd quarter. Sterling Capital Management LLC now owns 3,478 shares of the company’s stock worth $75,000 after buying an additional 3,108 shares in the last quarter. 44.58% of the stock is owned by institutional investors and hedge funds.
Immunome Company Profile
Immunome is a biotechnology company focused on discovering and developing therapies for cancer. It uses an antibody-discovery platform to identify targets and develop medicines intended to address areas of significant unmet medical need. The company’s research and development programs include targeted cancer treatments, such as antibody-based therapies and other drug candidates. Its portfolio has included investigational medicines for solid tumors and other cancers; these products are in development and are not necessarily approved for commercial use.
See Also
- Five stocks we like better than Immunome
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.
